Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront

被引：0
|
作者：
Jimenez, J. Torres [1 ,2 ]
Gorria, T. [2 ]
Auclin, E. [3 ]
Castro, N. [4 ]
Albarran-Artahona, V. [2 ]
Ruffinelli, J. C. [5 ]
Pinato, D. [6 ]
Routy, B. [7 ]
Nana, F. Aboubakar
Reyes, R. [2 ]
Vinolas, N. [2 ,9 ]
Blanc-Durand, F. [8 ,10 ]
Lopes, G. [11 ]
Nadal, E. [12 ]
Arasanz, H. [4 ,13 ]
Pascal, M. [2 ,9 ]
Teixido, C. [2 ]
Besse, B. [10 ]
Reguart, N. [2 ,9 ]
Mezquita, L. [2 ,9 ]
Jimenez, J. Torres [1 ,2 ]
机构：
[1] Hosp Univ Ramon & Cajal, Madrid, Spain
[2] Hosp Clin Barcelona, Barcelona, Spain
[3] Univ Paris, Hop European George Pompidou, AP HP, Paris, France
[4] Hosp Univ Navarra, Pamplona, Spain
[5] Catalan Inst Oncol, Barcelona, Spain
[6] Hammersmith Hosp, Imperial Coll London, London, England
[7] Ctr Hosp Univ Montreal CHUM, Montreal, PQ, Canada
[8] Catholic Univ Louvain, Brussels, Belgium
[9] August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumor, Barcelona, Spain
[10] Gustave Roussy, Villejuif, France
[11] Univ Miami, Miami, FL USA
[12] Catalan Inst Oncol, Lhospitalet De Llobregat, Spain
[13] IdiSNA, Oncoimmunol Grp, Navarrabiomed, Pamplona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Gender; Immunotherapy alone; Immunotherapy combination with chemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-09
引用
收藏
页码：S385 / S386
页数：2
相关论文
共 50 条
  • [21] Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real -World Study
    Daniel, Davey
    Gao, Ran
    Mhatre, Shivani K.
    Carroll, Charlotte
    Patel, Riddhi
    Park, Joseph
    Haggstrom, Daniel
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E49 - E49
  • [22] Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
    Wen, Miaomiao
    Xia, Jinghua
    Sun, Ying
    Wang, Xuejiao
    Fu, Xianghui
    Zhang, Yanning
    Zhang, Zhipei
    Zhou, Yongan
    Li, Xiaofei
    BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 183 - 190
  • [23] Prognostic value of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with combination of immunotherapy with chemotherapy: Preliminary results from a European retrospective study.
    Dimtrakopoulos, Foteinos-Ioannis D.
    Christopoulos, Petros
    Elshiaty, Mariam
    Daniello, Lea
    Pyrousis, Ioannis
    Kottorou, Anastasia E.
    Makatsoris, Thomas
    Kalofonos, Haralabos
    Koutras, Angelos
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients
    Mezquita, L.
    Gataa, I.
    Rossoni, C.
    Auclin, E.
    Kossai, M.
    Aboubakar, F.
    Le Moulec, S.
    Masse, J.
    Masson, M.
    Radosevic-Robin, N.
    Rouanne, M.
    Bluthgen, M.
    Caramella, C.
    Hendriks, L.
    Gazzah, A.
    Planchard, D.
    Pignon, J.
    Besse, B.
    Adam, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S351 - S352
  • [25] Immune-Related Adverse Events in Advanced Non-Squamous NSCLC Patients Treated with Upfront Checkpoint Inhibitors Combination
    Sultan, A.
    Thein, K.
    Swarup, S.
    Jahan, N.
    Tun, A.
    Meda, S.
    Arevalo, M.
    Naing, T.
    Htut, T.
    D'Cunha, N.
    Awasthi, S.
    Rehman, S.
    Tijani, L.
    Hardwicke, F.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S710 - S711
  • [26] Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy
    Smith, Margaret R.
    Wang, Yuezhu
    D'Agostino, Ralph
    Liu, Yin
    Ruiz, Jimmy
    Lycan, Thomas
    Oliver, George
    Miller, Lance D.
    Topaloglu, Umit
    Pinkney, Jireh
    Abdulhaleem, Mohammed N.
    Chan, Michael D.
    Farris, Michael
    Su, Jing
    Mileham, Kathryn F.
    Xing, Fei
    NPJ PRECISION ONCOLOGY, 2023, 7 (01)
  • [27] Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy
    Margaret R. Smith
    Yuezhu Wang
    Ralph D’Agostino
    Yin Liu
    Jimmy Ruiz
    Thomas Lycan
    George Oliver
    Lance D. Miller
    Umit Topaloglu
    Jireh Pinkney
    Mohammed N. Abdulhaleem
    Michael D. Chan
    Michael Farris
    Jing Su
    Kathryn F. Mileham
    Fei Xing
    npj Precision Oncology, 7
  • [28] Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy
    Andraos, Therese Y.
    Halmos, Balazs
    Cheng, Haiying
    Huntzinger, Calvin
    Shirvani, Shervin M.
    Ohri, Nitin
    CLINICAL LUNG CANCER, 2022, 23 (04) : 291 - 299
  • [29] Immunotherapy in advanced NSCLC Combination with Cytostatics or Monotherapy
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (04) : 232 - 232
  • [30] Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
    Zhou, Caicun
    Wang, Yina
    Zhao, Jun
    Chen, Gongyan
    Liu, Zhihua
    Gu, Kangsheng
    Huang, Meijuan
    He, Jianxing
    Chen, Jianhua
    Ma, Zhiyong
    Feng, Jifeng
    Shi, Jianhua
    Yu, Xinmin
    Cheng, Ying
    Yao, Yu
    Chen, Yuan
    Guo, Renhua
    Lin, Xiaoyan
    Wang, Zhehai
    Gao, Guanghui
    Wang, Quanren
    Li, Weixia
    Yang, Xinfeng
    Wu, Lihong
    Zhang, Jun
    Ren, Shengxiang
    CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1296 - 1304
12345